HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth
暂无分享,去创建一个
Carole A Bewley | Priyamvada Acharya | Peter D Kwong | C. Bewley | P. Acharya | P. Kwong | Sabrina Lusvarghi | Sabrina Lusvarghi
[1] P. Acharya,et al. Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. , 2013, Journal of medicinal chemistry.
[2] M. Nussenzweig,et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.
[3] Peter D. Kwong,et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions , 2014, Science.
[4] C. Bewley,et al. Solution Structure of the Monovalent Lectin Microvirin in Complex with Manα(1–2)Man Provides a Basis for Anti-HIV Activity with Low Toxicity* , 2011, The Journal of Biological Chemistry.
[5] C. Wright,et al. The 2.0 A structure of a cross-linked complex between snowdrop lectin and a branched mannopentaose: evidence for two unique binding modes. , 1996, Structure.
[6] M. Lecerf,et al. Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins : Implication for microbicide development , 2007, Journal of Translational Medicine.
[7] R. Shattock,et al. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. , 2007, Virology.
[8] J. Mcmahon,et al. Potent anti-HIV activity of scytovirin domain 1 peptide , 2006, Peptides.
[9] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[10] W A Hendrickson,et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.
[11] J. Hansen,et al. Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. , 1989, AIDS.
[12] D. Dimitrov,et al. Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity , 2013, PloS one.
[13] E. De Clercq,et al. Marked Depletion of Glycosylation Sites in HIV-1 gp120 under Selection Pressure by the Mannose-Specific Plant Lectins of Hippeastrum Hybrid and Galanthus nivalis , 2005, Molecular Pharmacology.
[14] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[15] Zheng Yang,et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Swanson,et al. A Lectin Isolated from Bananas Is a Potent Inhibitor of HIV Replication* , 2010, The Journal of Biological Chemistry.
[17] N. Meanwell,et al. In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 , 2012, Antimicrobial Agents and Chemotherapy.
[18] Tara Moayad,et al. Proper names in the arabic translation of harry potter and the goblet of fire , 2013 .
[19] J. Sodroski,et al. Tyrosine-sulfated Peptides Functionally Reconstitute a CCR5 Variant Lacking a Critical Amino-terminal Region* , 2002, The Journal of Biological Chemistry.
[20] E. Thiel,et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.
[21] Asim Kumar Debnath,et al. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. , 2005, Virology.
[22] E. Berger,et al. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. , 2004, Blood.
[23] Young Do Kwon,et al. Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. , 2011, Bioorganic & medicinal chemistry.
[24] J. Julien,et al. Structural insights into key sites of vulnerability on HIV‐1 Env and influenza HA , 2012, Immunological reviews.
[25] J. Sodroski,et al. Localized Changes in the gp120 Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155 , 2004, Journal of Virology.
[26] Asim K Debnath,et al. Rational design of HIV-1 entry inhibitors. , 2013, Methods in molecular biology.
[27] R. Sanders,et al. HIV‐1 envelope trimer has similar binding characteristics for carbohydrate‐binding agents as monomeric gp120 , 2013, FEBS letters.
[28] A. Gronenborn,et al. Structural basis of the anti-HIV activity of the cyanobacterial Oscillatoria Agardhii agglutinin. , 2011, Structure.
[29] T. Jouault,et al. Lectin-carbohydrate interactions and infectivity of human immunodeficiency virus type 1 (HIV-1). , 1992, AIDS research and human retroviruses.
[30] J. Mascola,et al. HIV-1: nature's master of disguise , 2003, Nature Medicine.
[31] M. Stefanidou,et al. MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques , 2012, PLoS pathogens.
[32] J. Mascola,et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.
[33] C. Bewley,et al. New carbohydrate specificity and HIV-1 fusion blocking activity of the cyanobacterial protein MVL: NMR, ITC and sedimentation equilibrium studies. , 2004, Journal of molecular biology.
[34] R. Means,et al. A role for carbohydrates in immune evasion in AIDS , 1998, Nature Medicine.
[35] John P. Moore,et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9 , 2013, Proceedings of the National Academy of Sciences.
[36] Baoshan Zhang,et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges , 2015, Nature.
[37] G. Shaw,et al. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. , 2008, Journal of molecular biology.
[38] J. Binley,et al. M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding , 2013, Retrovirology.
[39] A. Debnath,et al. Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site , 2014, PloS one.
[40] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[41] Characterization and carbohydrate specificity of pradimicin S. , 2012, Journal of the American Chemical Society.
[42] C. Bewley,et al. Crystal Structures of the HIV-1 Inhibitory Cyanobacterial Protein MVL Free and Bound to Man3GlcNAc2 , 2005, Journal of Biological Chemistry.
[43] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[44] D. Friend,et al. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. , 2013, Antiviral research.
[45] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[46] D. KwongPeter,et al. Structure of BMS-806, a Small-molecule HIV-1 Entry Inhibitor, Bound to BG505 SOSIP.664 HIV-1 Env Trimer , 2014 .
[47] Yuichiro Sato,et al. Primary Structure and Carbohydrate Binding Specificity of a Potent Anti-HIV Lectin Isolated from the Filamentous Cyanobacterium Oscillatoria agardhii* , 2007, Journal of Biological Chemistry.
[48] E. Rosenberg,et al. Functional Mimicry of a Human Immunodeficiency Virus Type 1 Coreceptor by a Neutralizing Monoclonal Antibody , 2005, Journal of Virology.
[49] J. Mcmahon,et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti‐HIV microbicide , 2007, Journal of medical primatology.
[50] J. Balzarini. Carbohydrate-Binding Agents: A Potential Future Cornerstone for the Chemotherapy of Enveloped Viruses? , 2007, Antiviral chemistry & chemotherapy.
[51] E. Berger. Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs , 2011, Current opinion in HIV and AIDS.
[52] L. Morris,et al. Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.
[53] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[54] G. Sapiro,et al. Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.
[55] J. Balzarini. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy , 2007, Nature Reviews Microbiology.
[56] Feng Gao,et al. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.
[57] C. Bewley,et al. Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex , 2001 .
[58] Ron Diskin,et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.
[59] L. Morris,et al. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. , 2013, Virology.
[60] J. Mcmahon,et al. The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors. , 2007, Journal of molecular biology.
[61] Tongqing Zhou,et al. Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.
[62] Clare Jolly,et al. HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent Synapse , 2004, The Journal of experimental medicine.
[63] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[64] C. Bewley,et al. Peptides from Second Extracellular Loop of C-C Chemokine Receptor Type 5 (CCR5) Inhibit Diverse Strains of HIV-1* , 2012, The Journal of Biological Chemistry.
[65] S W Lin,et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] S. Ōmura,et al. Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities. , 2001, Biochemical and biophysical research communications.
[67] L. Pannell,et al. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. , 2003, Biochemistry.
[68] Peter D. Kwong,et al. Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 , 2007, Science.
[69] D. Montefiori,et al. Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis. , 1987, AIDS research and human retroviruses.
[70] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[71] C. Bewley. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. , 2001, Structure.
[72] Brendan L Wilkinson,et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations , 2013, Retrovirology.
[73] S. Ōmura,et al. Actinohivin: specific amino acid residues essential for anti-HIV activity , 2010, The Journal of Antibiotics.
[74] A. Debnath,et al. Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. , 2011, ACS chemical biology.
[75] Q. Sattentau,et al. Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120 , 1999, Journal of Virology.
[76] J. Sodroski,et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. , 2008, Structure.
[77] Young Do Kwon,et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.
[78] Christoph Grundner,et al. Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120 , 2003, Cell.
[79] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[80] M. Boyd,et al. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. , 2001, The Journal of pharmacology and experimental therapeutics.
[81] Guillermo Sapiro,et al. Structural Mechanism of Trimeric HIV-1 Envelope Glycoprotein Activation , 2012, PLoS pathogens.
[82] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[83] Alexander W. Sun,et al. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. , 2012, Journal of medicinal chemistry.
[84] Craig B Wilen,et al. HIV: cell binding and entry. , 2012, Cold Spring Harbor perspectives in medicine.
[85] Young Do Kwon,et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility , 2009, Proceedings of the National Academy of Sciences.
[86] Ron Diskin,et al. Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies , 2013, The Journal of experimental medicine.
[87] J. Sodroski,et al. Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein , 2002, Journal of Virology.
[88] Peter D. Kwong,et al. Structure-Based Design, Synthesis and Validation of CD4-Mimetic Small Molecule Inhibitors of HIV-1 Entry: Conversion of a Viral Entry Agonist to an Antagonist , 2014, Accounts of chemical research.
[89] J. Mascola,et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection , 2014, Nature.
[90] K. Strebel,et al. Emergence of gp120 V3 Variants Confers Neutralization Resistance in an R5 Simian-Human Immunodeficiency Virus-Infected Macaque Elite Neutralizer That Targets the N332 Glycan of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein , 2013, Journal of Virology.
[91] Young Do Kwon,et al. Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.
[92] K. Van Laethem,et al. Actinohivin, a Broadly Neutralizing Prokaryotic Lectin, Inhibits HIV-1 Infection by Specifically Targeting High-Mannose-Type Glycans on the gp120 Envelope , 2010, Antimicrobial Agents and Chemotherapy.
[93] D. Schols,et al. Algal Lectins as Potential HIV Microbicide Candidates , 2012, Marine drugs.
[94] K. Gustafson,et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. , 2003, AIDS research and human retroviruses.
[95] J. Mascola,et al. Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. , 2013, Structure.
[96] L. Morris,et al. Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site , 2011, Journal of Virology.
[97] Richard T. Wyatt,et al. Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site , 2012, Journal of Virology.
[98] Wayne A Hendrickson,et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[99] J. Foulke,et al. Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection , 2014, Journal of Virology.
[100] E. Berger,et al. Neutralization of Human Immunodeficiency Virus Type 1 by sCD4-17b, a Single-Chain Chimeric Protein, Based on Sequential Interaction of gp120 with CD4 and Coreceptor , 2003, Journal of Virology.
[101] M. Churchill,et al. HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism , 2011, Journal of Virology.
[102] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[103] J C Gluckman,et al. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[104] E. Go,et al. Characterization of Glycosylation Profiles of HIV-1 Transmitted/Founder Envelopes by Mass Spectrometry , 2011, Journal of Virology.
[105] Barry R O'Keefe,et al. Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga Griffithsia sp.* , 2005, Journal of Biological Chemistry.
[106] T. Dam,et al. Multivalent lectin-carbohydrate interactions energetics and mechanisms of binding. , 2010, Advances in carbohydrate chemistry and biochemistry.
[107] L K Pannell,et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.
[108] T. Oki,et al. In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative , 1991, Antimicrobial Agents and Chemotherapy.
[109] D. Meyerholz,et al. Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae , 2009, Journal of Virology.
[110] J. Hoxie,et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.
[111] R. Wyatt,et al. Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. , 2008, Bioorganic & medicinal chemistry.
[112] Peter D Kwong,et al. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. , 2003, Virology.
[113] Ron Diskin,et al. Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.
[114] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[115] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[116] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[117] H. Katinger,et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.
[118] J. Sodroski,et al. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. , 1999, Biochemistry.
[119] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[120] Steven M. Wolinsky,et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.
[121] A. Gronenborn,et al. Structural Insights into the Anti-HIV Activity of the Oscillatoria agardhii Agglutinin Homolog Lectin Family* , 2012, The Journal of Biological Chemistry.
[122] E. Thiel,et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.
[123] N. Christensen,et al. Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo. , 2007, Virology.
[124] Baoshan Zhang,et al. Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 , 2013, Nature Structural &Molecular Biology.
[125] Rolf Kaiser,et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice , 2013, Proceedings of the National Academy of Sciences.
[126] D. Dimitrov,et al. Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains , 2013, Journal of Virology.
[127] S. Ōmura,et al. The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity , 2011, The Journal of Antibiotics.
[128] F. Gago,et al. Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes , 2006, Journal of Virology.
[129] William C. Olson,et al. Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes , 2001, Journal of Virology.
[130] E. Berger,et al. Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits…. , 2013, Structure.
[131] K. Van Laethem,et al. Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity , 2011, Retrovirology.
[132] M. Nussenzweig,et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission , 2013, The Journal of experimental medicine.
[133] D. Baltimore,et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission , 2012, Retrovirology.
[134] Joel E Gallant,et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy , 2003, AIDS.
[135] M. Farzan,et al. A Double-Mimetic Peptide Efficiently Neutralizes HIV-1 by Bridging the CD4- and Coreceptor-Binding Sites of gp120 , 2013, Journal of Virology.
[136] Dennis R Burton,et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens , 2010, Proceedings of the National Academy of Sciences.
[137] François Stricher,et al. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. , 2005, Structure.
[138] Florian Klein,et al. Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy , 2014, Cell.
[139] E. Dittmann,et al. Microvirin, a Novel α(1,2)-Mannose-specific Lectin Isolated from Microcystis aeruginosa, Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile* , 2010, The Journal of Biological Chemistry.
[140] Ying Sun,et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.
[141] I. Goldstein,et al. Crystal structure of banana lectin reveals a novel second sugar binding site. , 2005, Glycobiology.
[142] J. Bouchet,et al. Straightforward Selection of Broadly Neutralizing Single-Domain Antibodies Targeting the Conserved CD4 and Coreceptor Binding Sites of HIV-1 gp120 , 2012, Retrovirology.
[143] L. Stamatatos,et al. Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A , 2005, Journal of Virology.
[144] Tongqing Zhou,et al. Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.
[145] E. De Clercq,et al. Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins , 2004, Journal of Virology.
[146] David Baltimore,et al. Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.
[147] J. Balzarini,et al. Potential of carbohydrate‐binding agents as therapeutics against enveloped viruses , 2010, Medicinal research reviews.
[148] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[149] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[150] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.